Download Info Pack
Why Cordlife
Why Cordlife

Technology And Quality Pioneer

Sepax®2 Maximises Cell Recovery to Increase Transplant Success
FIRST in Singapore

Automated Stem Cell Processing System
The Standard in Cord Blood Banking

Stem cell isolation is a critical step in cord blood banking. It affects the number of stem cells that can be harvested or recovered from the cord blood. Cell recovery rates are critical because a higher number of stem cells could enhance the success of the transplant or treatment. That's why Cordlife has invested in the Sepax®2 automated stem cell processing technology, a safe, sterile and fully automated cord blood processing technology - so you get more stem cells for maximum transplant success*.

Sepax Technology

Sepax®2 versus other processing methods

Cordlife is the first private cord blood bank in Singapore to offer the Sepax®2 automated processing technology. This Swiss-made and U.S. FDA-cleared device can recover as high as 99.88%1 of Total Nucleated Cells (TNC) from cord blood. It also a functionally closed processing system which ensures the sterility of the cord blood by eliminating exposure to air contaminants.

Features of Sepax® 2 and what it means to You, as a Parent

Feature Benefits to You
Swiss Quality
  • Swiss-made patented automated cord blood processing system.
  • Advanced technology with new protocols.
  • We process your baby's cord blood with high Swiss precision, reliable, state-of-the-art technology.
Fully Automated
  • Requires no external centrifuge or operator intervention during processing.
  • Controlled, smooth and precise cell separation by an advanced optical sensor.
  • The yield from cord blood processing is consistent, with reproducible high results (that is, cell recoveries).
Cell Recovery
  • Able to achieve as high as 99.88%1 Total Nucleated Cells (TNC) recovery rate.
  • More cells are recovered / harvested from your baby's cord blood for future treatment (if needed), allowing better chance of a successful transplant.
Safety
  • Closed processing system.
  • Every baby's cord blood unit is fully monitored and traceable throughout each procedure
  • Possesses a troubleshooting system. Even in cases of power failure, all cord blood units can be processed without having errors.
  • Processing of your baby's cord blood unit is safe and highly sterile, leaving zero opportunity for error.
Unique
  • The only cord blood processing technology that processes one cord blood unit at a time.
  • Sepax®2 is calibrated and tested before every procedure, treating every cord blood unit like its first one.
  • Uniquely adapted to the qualities of each and every baby's stem cells, customizing every process accordingly.
  • Prevent any sample mix-up and eliminates any possible cross-contamination of your baby's precious cord blood unit.
Regulatory Approvals
  • Cleared by U.S. FDA, approved by European Union (evidenced by CE Mark), and Japan MHLW (Ministry of Health and Labor Welfare)
  • Complies with the highest quality standards such as AABB & FACT-Netcord3
  • Meets international health, safety and environmental requirements to ensure consumer safety.
Statistics/Evidence
  • An advanced cord blood processing technology with proven transplant track record.
  • World's most tried and trusted automated system.
  • Over 1 million cord blood units2 have been processed by the Sepax® System in over 50 countries, this is almost half of the worldwide processing procedures for cord blood inventory.
  • Trusted by majority of the world's leading public and private cord blood banks.
  • The Sepax® system has been chosen by over 75% of the Netcord organizations that group the leading public cord blood banks around the world.
  • Proven technology, equipment and consumables that are used by industry leader  - the true validation on the quality of the Sepax® automated processing technology.

First Bank

  • Cordlife is the first private cord blood bank in Singapore to offer automated cord blood processing with Sepax®2.
  • Our investment in advance technology now and in the future means you and your family will benefit from any future technology upgrade for the long-term storage of your baby's stem cells.

References
1. Cordlife’s actual data as of 6 September 2017
2. Biosafe, manufacturer of Sepax® (figures accurate as of 31 March 2013)

*Kindly note that the above mentioned is general information only. Please refer to the Cordlife Service Agreement for full details and its terms and conditions. Cordlife Group Limited reserves the rights to amend or cancel any of the benefits listed above without prior notice. International quality standards may differ between the time of enrolment and time of release of your baby's cord blood unit for transplant. All reasonable efforts will be made to adhere to the prevailing standards at the time of release of your baby's cord blood unit. HLA testing and CFU Assay may or may not cease to become a mandatory quality check.Cordlife has taken added insurance coverage, to safeguard you and your family from financial loss that results from direct malpractice*.



DCR No. : 1542, June 2019